Post-lumbar puncture headache is the main adverse event from lumbar puncture and occurs in 3.5% to 33% of patients, causing functional and socio-professional disability. We searched the post-lumbar puncture headache literature and, based on this review and personal expertise, identified and addressed 19 frequently asked questions regarding post-lumbar puncture headache risk factors and prevention. Among the nonmodifiable factors, older age is associated with a lower incidence of post-lumbar puncture headache, while female sex, lower body mass index, and history of headache might be associated with increased risk. The use of atraumatic, noncutting needles is the most effective intervention for post-lumbar puncture headache prevention. These needles are not more difficult to use than cutting needles. Other commonly recommended measures (eg, fluid supplementation, caffeine) appear unhelpful, and some (eg, bed rest) may worsen post-lumbar puncture headache.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.annemergmed.2021.02.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse events of nusinersen: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.
Expert Opin Drug Saf
December 2024
Department of Neurology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing, China.
Article Synopsis
- The study investigates the safety of Nusinersen, an FDA-approved drug for Spinal Muscular Atrophy, using the FAERS database to analyze adverse events.
- It employs various statistical models to identify Nusinersen-related adverse reactions, finding 230 new adverse terms and highlighting potential side effects like cardiac arrest and autism spectrum disorder.
- The findings suggest that younger patients may face risks of upper respiratory infections, while older patients could show symptoms of post-lumbar puncture syndrome, underscoring the need for careful monitoring.
Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study.
Neurol Int
October 2024
Department of Developmental Neurology, Medical University of Gdansk, 80-952 Gdansk, Poland.
Background: Spinal muscular atrophy (SMA) is an inherited neuromuscular disease characterized by progressive muscle weakness and atrophy due to the absence of the survival motor neuron 1 () gene. SMA is classified into types 0 through 4 based on the age of symptom onset and the severity of motor function decline. Recent advances in SMA treatment, including nusinersen, onasemnogene abeparvovec, and risdiplam, have significantly improved the prognosis of SMA patients.
View Article and Find Full Text PDFComplication of post-lumbar puncture.
J Am Coll Emerg Physicians Open
December 2024
Department of Radiology Tata Memorial Hospital Mumbai India.
Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti-α-Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults.
J Clin Pharmacol
November 2024
BioArctic AB, Stockholm, Sweden.
Exidavnemab is a monoclonal antibody (mAb) with a high affinity and selectivity for pathological aggregated forms of α-synuclein and a low affinity for physiological monomers, which is in clinical development as a disease-modifying treatment for patients with synucleinopathies such as Parkinson's disease. Safety, tolerability, pharmacokinetics, immunogenicity, and exploratory biomarkers were assessed in two separate Phase 1 single ascending dose studies, including single intravenous (IV) (100 to 6000 mg) or subcutaneous (SC) (300 mg) administration of exidavnemab in healthy volunteers (HVs). Across the two studies, a total of 98 Western, Caucasian, Japanese, and Han Chinese HVs were enrolled, of which 95 completed the study.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the safety, tolerability, and pharmacokinetics of BIIB078, an investigational treatment targeting the genetic cause of amyotrophic lateral sclerosis (ALS) linked to the C9orf72 gene mutation.
- The trial involved 106 participants with C9orf72-associated ALS, who were randomly assigned to receive varying doses of BIIB078 or a placebo over a treatment period of three to six months.
- Results showed that all participants experienced at least one adverse event, mostly mild or moderate, indicating that while BIIB078 did pose some risks, it did not lead to a high rate of treatment discontinuation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!